Last reviewed · How we verify
local injection
The local injection, marketed by Ahi Evran University Education and Research Hospital, holds a niche position in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and competitive positioning.
At a glance
| Generic name | local injection |
|---|---|
| Also known as | local corticosteroid injection |
| Sponsor | Ahi Evran University Education and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Treatment of Crohn's Complex Perianal Fistulas With Tissue Transplantation by Local Injection of Micro-fragmented Autologous Adipose Tissue. (NA)
- A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (PHASE2, PHASE3)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia (PHASE3)
- Effects of Local Ketamine in Orthognathic Procedures (NA)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |